These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35804969)

  • 1. Magnetic Resonance Spectroscopy in Diagnosis and Follow-Up of Gliomas: State-of-the-Art.
    Galijasevic M; Steiger R; Mangesius S; Mangesius J; Kerschbaumer J; Freyschlag CF; Gruber N; Janjic T; Gizewski ER; Grams AE
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic approach for tumor delineation in glioma surgery: 3D MR spectroscopy image-guided resection.
    Zhang J; Zhuang DX; Yao CJ; Lin CP; Wang TL; Qin ZY; Wu JS
    J Neurosurg; 2016 Jun; 124(6):1585-93. PubMed ID: 26636387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas.
    Ikeguchi R; Shimizu Y; Abe K; Shimizu S; Maruyama T; Nitta M; Abe K; Kawamata T; Kitagawa K
    Mult Scler Relat Disord; 2018 Nov; 26():77-84. PubMed ID: 30237108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic Resonance Imaging and Proton Magnetic Resonance Spectroscopy for Differentiating Between Enhanced Gliomas and Malignant Lymphomas.
    Ohba S; Murayama K; Abe M; Hasegawa M; Hirose Y
    World Neurosurg; 2019 Jul; 127():e779-e787. PubMed ID: 30951915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative assessment of gliomas by proton magnetic resonance spectroscopy.
    Oshiro S; Tsugu H; Komatsu F; Abe H; Onishi H; Ohmura T; Iwaasa M; Sakamoto S; Fukushima T
    Anticancer Res; 2007; 27(6A):3757-63. PubMed ID: 17970039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and prognostic value of 18F-DOPA PET and 1H-MR spectroscopy in pediatric supratentorial infiltrative gliomas: a comparative study.
    Morana G; Piccardo A; Puntoni M; Nozza P; Cama A; Raso A; Mascelli S; Massollo M; Milanaccio C; Garrè ML; Rossi A
    Neuro Oncol; 2015 Dec; 17(12):1637-47. PubMed ID: 26405202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced MR imaging in hemispheric low-grade gliomas before surgery; the indications and limits in the pediatric age.
    Gaudino S; Russo R; Verdolotti T; Caulo M; Colosimo C
    Childs Nerv Syst; 2016 Oct; 32(10):1813-22. PubMed ID: 27659824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of MR spectroscopy for assessment of glioma grading.
    Bulik M; Jancalek R; Vanicek J; Skoch A; Mechl M
    Clin Neurol Neurosurg; 2013 Feb; 115(2):146-53. PubMed ID: 23237636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI.
    Yang D; Korogi Y; Sugahara T; Kitajima M; Shigematsu Y; Liang L; Ushio Y; Takahashi M
    Neuroradiology; 2002 Aug; 44(8):656-66. PubMed ID: 12185543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic potential of short echo time MR spectroscopy of gliomas with single-voxel and point-resolved spatially localised proton spectroscopy of brain.
    Kaminogo M; Ishimaru H; Morikawa M; Ochi M; Ushijima R; Tani M; Matsuo Y; Kawakubo J; Shibata S
    Neuroradiology; 2001 May; 43(5):353-63. PubMed ID: 11396738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.
    Choi C; Raisanen JM; Ganji SK; Zhang S; McNeil SS; An Z; Madan A; Hatanpaa KJ; Vemireddy V; Sheppard CA; Oliver D; Hulsey KM; Tiwari V; Mashimo T; Battiste J; Barnett S; Madden CJ; Patel TR; Pan E; Malloy CR; Mickey BE; Bachoo RM; Maher EA
    J Clin Oncol; 2016 Nov; 34(33):4030-4039. PubMed ID: 28248126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amide Proton Transfer Imaging Allows Detection of Glioma Grades and Tumor Proliferation: Comparison with Ki-67 Expression and Proton MR Spectroscopy Imaging.
    Su C; Liu C; Zhao L; Jiang J; Zhang J; Li S; Zhu W; Wang J
    AJNR Am J Neuroradiol; 2017 Sep; 38(9):1702-1709. PubMed ID: 28729292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
    Chaumeil MM; Radoul M; Najac C; Eriksson P; Viswanath P; Blough MD; Chesnelong C; Luchman HA; Cairncross JG; Ronen SM
    Neuroimage Clin; 2016; 12():180-9. PubMed ID: 27437179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative magnetic resonance spectroscopy improves diagnostic accuracy in a series of neurosurgical dilemmas.
    Rao PJ; Jyoti R; Mews PJ; Desmond P; Khurana VG
    Br J Neurosurg; 2013 Oct; 27(5):646-53. PubMed ID: 23461752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance spectroscopy detection of high lipid levels in intraaxial tumors without central necrosis: a characteristic of malignant lymphoma.
    Yamasaki F; Takayasu T; Nosaka R; Amatya VJ; Doskaliyev A; Akiyama Y; Tominaga A; Takeshima Y; Sugiyama K; Kurisu K
    J Neurosurg; 2015 Jun; 122(6):1370-9. PubMed ID: 25748300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors.
    Server A; Josefsen R; Kulle B; Maehlen J; Schellhorn T; Gadmar Ø; Kumar T; Haakonsen M; Langberg CW; Nakstad PH
    Acta Radiol; 2010 Apr; 51(3):316-25. PubMed ID: 20092374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.
    Molloy AR; Najac C; Viswanath P; Lakhani A; Subramani E; Batsios G; Radoul M; Gillespie AM; Pieper RO; Ronen SM
    Theranostics; 2020; 10(19):8757-8770. PubMed ID: 32754276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic accuracy of proton magnetic resonance spectroscopy and perfusion-weighted imaging in brain gliomas follow-up: a single institutional experience.
    Anselmi M; Catalucci A; Felli V; Vellucci V; Di Sibio A; Gravina GL; Di Staso M; Di Cesare E; Masciocchi C
    Neuroradiol J; 2017 Jun; 30(3):240-252. PubMed ID: 28627984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of proton magnetic resonance spectroscopy with fluorine-18 2-fluoro-deoxyglucose positron emission tomography for assessment of brain tumor progression.
    Imani F; Boada FE; Lieberman FS; Davis DK; Deeb EL; Mountz JM
    J Neuroimaging; 2012 Apr; 22(2):184-90. PubMed ID: 21155917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists.
    Kim H; Kim S; Lee HH; Heo H
    Korean J Radiol; 2016; 17(5):620-32. PubMed ID: 27587950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.